Hydroxychloroquine in Blocking Autophagy in Patients With Prostate Cancer Undergoing Surgery or Active Surveillance
Stopped early · Early Phase 1
Conditions studied: Prostate Carcinoma
In brief
This phase 0 trial studies hydroxychloroquine in blocking autophagy in patients with prostate cancer who are undergoing surgery or active surveillance. Autophagy is a process in which cells break down some parts of themselves to stay alive during times of stress, such as starvation. This may allow cancer cells to survive damage from chemotherapy. Hydroxychloroquine may block this process from happening.
Key facts
- Study ID
- NCT02421575
- Run by
- Rutgers, The State University of New Jersey
- People needed
- 4
- Starts
- 2012-07-01
- Expected to finish
- 2016-02-26
- Last updated by the study team
- 2017-02-02
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
You may qualify if…
- Signed written informed consent
- Have abnormal digital rectal examination, or abnormal prostate specific antigen (> 4.0 ng/ml), or obstructing prostate, or biopsy proven prostate cancer
- Scheduled for prostate surgery, i.e. transurethral resection of the prostate (TURP) or prostatectomy
- Planned to be treated by active surveillance
You may not qualify if…
- Patients on treatment for rheumatoid arthritis or systemic lupus erythematosus
- Patients with psoriasis
- Patients receiving any disease-modifying anti-rheumatic drug (DMARD)
- Active clinically significant infection requiring antibiotics
- Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency
- Patients taking other commercially available medications which may theoretically either stimulate or inhibit autophagy, which are calcitriol and chloroquine
- Patients taking medications which may lead to interactions with hydroxychloroquine, including penicillamine, telbivudine, botulinum toxin, digoxin, and propafenone
- Patients must not have prior visual field changes from prior 4-aminoquinoline compound use
- Must not be taking hydroxychloroquine for treatment or prophylaxis of malaria
- History of hypersensitivity to 4-aminoquinoline compound
Where it is running
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.